Moxalactam treatment of anaerobic infections in cancer patients | Zendy

Hjalmar Lagast | Zendy; F. Meunier–Carpentier | Zendy; Jean Klášterský | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Moxalactam treatment of anaerobic infections in cancer patients

Author(s) -

Hjalmar Lagast,

F. Meunier–Carpentier,

Jean Klášterský

Publication year - 1982

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.22.4.604

Subject(s) - moxalactam , anaerobic exercise , medicine , microbiology and biotechnology , biology , antibiotics , cephalosporin , physiology

Of 30 patients with predominantly anaerobic localized infections superimposed on chronic tissue damage related to trauma, ischemia, or tumor, 22 (73%) responded satisfactorily to moxalactam therapy. Moxalactam-resistant anaerobic pathogens emerged in two patients and were responsible for treatment failure. In six patients, two of whom also acquired resistant anaerobic pathogens, isolation of moxalactam-resistant aerobic pathogens increased during therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research